CASl's deal flow originates exclusively from within the Czech Academy of Sciences, ranked 10th globally among funded R&D institutions in 2024. Spanning 52 research institutes and over 8,000 scientists - the Academy generates a continuous pipeline of breakthrough technologies across deep tech, life sciences, and health tech.

Through its close partnership with CETAV, the Academy's technology transfer centre, CASI gains privileged early-stage access to over 120 active commercialization projects-identifying the most investable opportunities before they reach the broader market.